“The management of advanced prostate cancer has evolved significantly, driven in part by the integration of diverse biomarkers that guide treatment decisions from diagnosis through progression,” says Nedim Ruhotina, MD.
Risk score derived from cardiovascular reactivity predictive of adverse outcomes beyond traditional cardiovascular risk factors in CAD
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.
Acute toxicity after radiotherapy is associated with late toxicity and quality of life in patients with prostate cancer, data suggest.
Smerina and Pearlman discuss recent research collaborations in the field of sexual medicine.
Personalized vaccine targets key driver mutations and induces antitumor immunity in fully resected high-risk clear cell renal cell carcinoma
The Prostate Cancer (PCa) Guidelines Panel have prepared this guidelines document to assist medical professionals in the evidence-based management of PCa.
An umbrella review of steroidal and nonsteroidal mineralocorticoid receptor antagonists (MRA) support variable benefits in chronic kidney disease (CKD).
Dr. Pant offered insights on the key findings of zanidatamab’s efficacy and safety in HER2-positive BTC.
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Read our Cookies
